卡格列净
医学
肾病
2型糖尿病
达帕格列嗪
糖尿病肾病
糖尿病
临床试验
2型糖尿病
内科学
内分泌学
药理学
重症监护医学
泌尿科
作者
Vlado Perkovic,Meg Jardine,Bruce Neal,Séverine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,Robert Edwards,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang
标识
DOI：10.1056/nejmoa1811744
摘要
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
BowieHuang
GingerF
Criminology34
淡淡土豆
无极微光
yznfly
子车茗
VDC
eric888
Harry
tuanheqi
带头大哥
蚊蚊爱读书
freyaaaaa
BareBear
fei
SIREN
Wuyt
sqrt138
bjbmtxy
pcr163
pluto
wanci
皖公网安备34019202002308
